Trust Signals
Key Takeaways
- BPC 159 and BPC 157 are the same 15-amino-acid peptide; the different number is a catalog or database artifact, not a distinct compound.
- The confirmed amino acid sequence is GEPPPGKPADDAGLV, molecular weight approximately 1419.5 g/mol; any product claiming a different sequence under either name is mislabeled.
- As of 2026, no published human RCT confirms efficacy for BPC 157 in any indication; the evidence base is almost entirely rodent studies from one primary research group.
- Lyophilized BPC 157 stored incorrectly above minus 20 degrees Celsius before reconstitution loses potency over time; degradation is not visible to the naked eye.
- The FDA has raised regulatory concerns about compounded BPC 157; its legal status in the United States for human use is actively restricted as of this writing.
Direct Answer: BPC 159 vs BPC 157
BPC 159 and BPC 157 are the same peptide. The sequence, molecular weight, and mechanism are identical. The number 159 appears as an alternate catalog identifier in some supplier databases and certificates of analysis, not as a chemically distinct variant. No separate compound called BPC 159 exists in peer-reviewed literature.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Where does the naming confusion come from?
- What is the actual sequence and structure?
- What does the evidence actually show?
- How does BPC 157 work mechanistically?
- What most pages get wrong about BPC 157
- BPC 157 vs alternatives: honest comparison
- Storage and stability: the chemistry behind the rules
- How to read a BPC 157 COA and product label
- Legal and regulatory status
- FAQ
- Sources
Where Does the Naming Confusion Come From?
BPC 157 was named "Body Protection Compound 157" by researcher Predrag Sikiric and colleagues at the University of Zagreb, where most of the primary animal research was conducted. The number 157 is a laboratory research designation for this specific 15-amino-acid fragment isolated from human gastric juice protein.
The number 159 appears in certain chemical supplier catalogs and CAS-adjacent database entries as an internal product code. Some manufacturers use it interchangeably on documentation. It does not correspond to a different length, modification, or salt form. A search of PubMed for "BPC 159" yields no results as a distinct compound; all mechanistic and animal research uses the BPC 157 designation exclusively.
If a vendor markets BPC 159 as something different from or superior to BPC 157, that is a marketing claim with no scientific basis.
What Is the Actual Sequence and Structure?
BPC 157 is a 15-amino-acid peptide. The sequence is:
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV)
Key structural facts:
- Molecular formula: C62H98N16O22
- Molecular weight: approximately 1419.5 g/mol
- Most commercially available as the acetate salt
- Linear peptide, no disulfide bonds
- The three consecutive proline residues (positions 3 to 5) create a rigid turn that is thought to influence its binding interactions and resistance to some proteolytic enzymes
Any product labeled BPC 157 or BPC 159 that does not match this sequence on mass spectrometry confirmation is a different or impure compound.
What Does the Evidence Actually Show?
The evidence base for BPC 157 is large in volume but narrow in quality. The vast majority of published work comes from Sikiric's group in Zagreb, working almost exclusively in rodent models.
| Claimed Benefit | Best Available Evidence | Effect Direction | Confidence |
|---|---|---|---|
| Tendon and ligament healing | Rodent studies (multiple, same group) | Positive in animals | Very Low (human) |
| Gut mucosal healing / IBD | Rodent studies; one Phase II trial initiated, unpublished results | Positive in animals; human unclear | Very Low (human) |
| Bone healing | Rodent studies | Positive in animals | Very Low (human) |
| Neuroprotection | Rodent studies | Positive in animals | Very Low (human) |
| Angiogenesis promotion | Cell culture and rodent data | Positive in vitro/animals | Low (mechanism only in humans) |
| Systemic anti-inflammatory effect | Rodent studies | Positive in animals | Very Low (human) |
| Safety in humans | Limited human exposure data; no large safety RCT | No major signals reported anecdotally | Very Low |
The honest summary: BPC 157 has a consistent and interesting signal in rodent injury models. That signal has not been tested in powered, controlled human trials. The gap between animal efficacy and human proof is the defining limitation of this compound.
How Does BPC 157 Work Mechanistically?
Rodent and cell-culture research points to several overlapping pathways. These are mechanisms, not proven human benefits:
- GH receptor upregulation: Sikiric's group reported that BPC 157 appears to upregulate growth hormone receptor expression in various tissues in rodents, potentially amplifying endogenous GH signaling without raising GH levels itself. This is a mechanistic observation from animal work, not a measured human outcome.
- Nitric oxide modulation: Studies in rodent vascular models suggest BPC 157 influences nitric oxide synthesis, which could contribute to vasodilation and angiogenesis. The exact receptor target responsible has not been definitively identified in peer-reviewed literature.
- VEGF pathway interaction: Animal data suggests BPC 157 promotes vascular endothelial growth factor (VEGF) expression, supporting new blood vessel formation at injury sites. This may underlie the tendon and wound-healing observations in rodent models.
- FAK-paxillin pathway: Cell migration assays show BPC 157 activates focal adhesion kinase (FAK) and paxillin signaling, both important for cell movement into wound sites. This is cell-culture data and does not prove the same occurs in intact human tissue at achievable concentrations.
- Protease stability: The triple-proline sequence creates steric bulk that resists some digestive proteases, which is why oral bioavailability in rodents is measurable. In humans, the oral bioavailability has not been formally quantified in a published pharmacokinetic study.
What the mechanism does NOT prove: That any of these pathways produces clinically meaningful effect sizes in humans at the doses studied, or that the peptide reaches target tissues in humans at sufficient concentrations after oral or subcutaneous administration.
What Most Pages Get Wrong About BPC 157
1. Oral bioavailability is assumed, not confirmed in humans. Rodent studies show measurable systemic effects from oral BPC 157, and the triple-proline motif does resist some proteolysis. However, no published human pharmacokinetic study quantifies oral bioavailability in humans. Extrapolating rodent gut physiology to humans is not straightforward, and peptide oral bioavailability in humans is generally poor without specific delivery technology.
2. "BPC 159" as a marketing differentiator is fabricated value. Some vendors imply BPC 159 is a purer, newer, or enhanced form. There is no scientific literature supporting this distinction. It is the same peptide, and any purity claim must be verified on the product's own COA, not from the name.
3. Research concentration is not research independence. The majority of BPC 157 animal studies originate from one research group. This is not disqualifying, but it means the positive findings have not been widely independently replicated, which is a significant limitation when assessing how robust the signal actually is.
4. Acetate vs. other salt forms matter for dosing math. BPC 157 acetate contains acetate ions that contribute to the total molecular weight. The free-base peptide mass differs from the acetate salt mass. Some COAs report purity on the salt form; others on the free-base equivalent. This affects actual peptide dose per milligram of powder. If a supplier does not specify which form is being quantified, you cannot accurately calculate dose.
5. Degradation is invisible. A vial of degraded, reconstituted BPC 157 looks identical to a potent one. Color, clarity, and consistency tell you nothing. Only HPLC-validated third-party testing of the reconstituted product would confirm integrity, which no consumer does in practice.
BPC 157 vs Alternatives: Honest Comparison
| Comparison | BPC 157 | Alternative | Where BPC 157 Loses |
|---|---|---|---|
| vs. TB-500 (Thymosin Beta-4 fragment) for tissue repair | Angiogenesis and GH-receptor modulation in rodents; no human RCT | Actin polymerization, cell migration; also animal data only; larger molecule (43 amino acids) | Neither has human RCT data; TB-500's mechanism (actin-based) is biochemically better characterized |
| vs. Standard physical therapy for tendon injury | Rodent tendon healing data, positive but unconfirmed in humans | Physical therapy has robust human RCT evidence for tendinopathy outcomes | BPC 157 loses clearly; no human trial supports equivalence or superiority |
| vs. PRP (Platelet-Rich Plasma) for tendon repair | No human comparative data | PRP has multiple human RCTs, mixed but existent efficacy signal | BPC 157 loses; PRP has actual human trial data, even if effect sizes are debated |
| vs. Mesalamine for IBD | Animal IBD models show mucosal healing; no human efficacy trial | Mesalamine has extensive RCT data, FDA approval, decades of human safety data | BPC 157 loses by a large margin for any clinical application |
| vs. Collagen peptides (oral) for connective tissue | Mechanism more specific; evidence largely animal | Collagen peptides have multiple human RCTs for skin and joint outcomes, modest but real effect sizes | BPC 157 loses on human evidence; collagen peptides have actual human RCTs |
Storage and Stability: The Chemistry Behind the Rules
The instruction to store lyophilized peptides at minus 20 degrees Celsius is not arbitrary caution. Here is why it matters for BPC 157 specifically:
Peptide bond hydrolysis: Even in the dry state, trace moisture catalyzes hydrolysis of peptide bonds. Lower temperature dramatically slows this reaction rate according to Arrhenius kinetics. Storing lyophilized BPC 157 at room temperature accelerates hydrolytic degradation compared to frozen storage, even though the powder appears unchanged.
Oxidation of susceptible residues: BPC 157 contains a glutamate (Glu) and aspartate (Asp) residues that, while not sulfur-containing, can participate in deamidation reactions under warm, moist conditions. The result is a structurally altered peptide that may retain some sequence identity but has altered charge distribution.
Post-reconstitution: Once dissolved in bacteriostatic water, the peptide is in aqueous solution and far more susceptible to both hydrolysis and microbial degradation. Refrigeration at 2 to 8 degrees Celsius slows but does not stop degradation. Most conservative guidance suggests using reconstituted solution within 2 to 4 weeks, though no formal human-use stability study with defined endpoints exists in published literature for this specific formulation.
Freeze-thaw cycles: Each freeze-thaw cycle can cause local concentration gradients, ice crystal formation, and partial aggregation of peptide chains. If using aliquots, freeze separate small volumes rather than repeatedly thawing the same vial.
Light exposure: UV exposure can cause photodegradation of aromatic and some non-aromatic residues. Store in amber vials or wrapped in foil.
The practical rule: lyophilized powder frozen and dry is stable for months to years; reconstituted and refrigerated, treat as perishable within weeks.
How to Read a BPC 157 COA and Product Label
A legitimate certificate of analysis for BPC 157 (or any product labeled BPC 159) should contain all of the following. If any are absent, request them or choose a different supplier:
| COA Field | What to Look For | Red Flag |
|---|---|---|
| Amino acid sequence | GEPPPGKPADDAGLV confirmed | Sequence not listed or differs |
| Molecular weight | Approximately 1419.5 g/mol (free base) or labeled salt form equivalent | Wrong MW, or MW not listed |
| Purity by HPLC | 98% or above for research grade | Below 95%, or method not specified |
| Mass spectrometry confirmation | MS data confirming correct molecular ion | Absent on any product claiming high quality |
| Salt form specification | Acetate or TFA salt clearly stated | Not stated; affects dosing calculation |
| Lot number and date | Traceable lot, recent manufacture | No lot number; undated COA |
| Testing laboratory | Named third-party lab, independent of manufacturer | In-house testing only |
Dosing math note: If your COA reports purity as a percentage of the acetate salt and you are calculating peptide dose by mass, the actual free-base peptide content per milligram will be slightly lower than the labeled amount. For research purposes, 5 mg of BPC 157 acetate at 98% purity does not equal exactly 5 mg of free-base peptide. This distinction matters most at higher dose ranges or when comparing between suppliers using different salt forms.
Legal and Regulatory Status
BPC 157 is not approved by the FDA for any indication in humans. As of 2026, the FDA has included BPC 157 among substances subject to compounding restrictions, citing concerns about adequate safety and efficacy data for compounded human use. Practitioners and patients should verify current regulatory status in their jurisdiction before any use. BPC 157 also appears on WADA's monitoring list due to its classification as a potential growth factor modifier; competitive athletes should consult current WADA prohibited list documents directly.
FAQ
Sources
- Sikiric P, Seiwerth S, Rucman R, et al. "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." Current Pharmaceutical Design. 2011;17(16):1612-1632.
- Sikiric P, Seiwerth S, Rucman R, et al. "Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157." European Journal of Pharmacology. 2012;703(1-3):1-10.
- Chang CH, Tsai WC, Lin MS, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." Journal of Applied Physiology. 2011;110(3):774-780.
- Gwyer D, Wragg NM, Wilson SL. "Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing." Cell and Tissue Research. 2019;377(2):153-159.
- Sikiric P, Hahm KB, Blagaic AB, et al. "Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response." Biomedicines. 2020;8(9):344.
- U.S. Food and Drug Administration. "Compounding and the FDA: Questions and Answers." FDA.gov. Accessed 2026.
- World Anti-Doping Agency. "Prohibited List." WADA-AMA.org. Updated annually; consult current version for BPC 157 status.
- Cerovecki T, Bojanic I, Brcic L, et al. "Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat." Journal of Orthopaedic Research. 2010;28(9):1155-1161.